Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
55 Corporate Drive , Bridgewater, NJ, 08807, US
ADEL-Y01 is a potential first-in-class antibody therapy for Alzheimer's disease.
By: Charlie Sternberg
This partnership will help develop next-generation B-Cell depletion therapy for various autoimmune diseases.
By: Rachel Klemovitch
Approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria.
EVOQ and Sanofi will jointly conduct research activities, with Sanofi assuming responsibility for global development and commercialization.
The additional funding will accelerate investment in biotech and digital health innovation, focusing on immunology, rare diseases, neurology, and vaccines.
The Ridgefield sterile fill-finish and packaging facility is now part of Thermo Fisher's pharma services business within its Laboratory Products and Biopharma Services segment.
Helps address the root causes of ITP through multi-immune modulation, targeting different pathways across the immune system.
Approval is based on GMMG-HD7 phase 3 study for those who are transplant-eligible, newly diagnosed with multiple myeloma.
Will gain access to Vicebio’s Molecular Clamp technology, which enables development of next-gen multivalent vaccines against respiratory pathogens.
Thermo Fisher to acquire Sanofi’s steriles manufacturing site in Ridgefield, NJ and continue to manufacture a portfolio of therapies for Sanofi.
Sanofi plans to explore the oral dual JAK/SYK inhibitor’s potential in a new indication not previously studied through a phase 1 study.
Expands portfolio in rare immunological disease and adds early-stage pipeline in immunology
The acquisition enhances Sanofi’s early-stage pipeline and includes VG-3927.
Will boost manufacturing and research & development efforts in the country.
Aims to accelerate the development of HXN-1002 and HXN-1003.
Enter the destination URL
Or link to existing content
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !
